NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
16 May 2024
| Name: | MEDIBIO LIMITED (MEB) (This company subsequently changed its name to TRIVARX LTD. You should refer to that name for Status.) | ||||||
| ISIN: | AU000000MEB8 | ||||||
| Date of Listing: | 29 January 2001 | ||||||
| Subsequent Names: |
| ||||||
| Former Names: |
|
Stock Exchange Status: (updated daily)
This company subsequently changed its name to TRIVARX LTD. You should refer to that name for Stock Exchange Status.Legal Status: (updated monthly)
ACN: 008 130 336ABN: 58 008 130 336
Registration Date: 05 March 1987
Capital Gains Tax (CGT) Status: (updated at least quarterly)
This company subsequently changed its name and is now TRIVARX LTD. You should refer to that name for Capital Gains Tax Status.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| TRIVARX LTD | 16/10/2023 | |
| MEDIBIO LIMITED | 01/12/2014 | 16/10/2023 |
| BIOPROSPECT LIMITED | 01/12/2014 |
Computershare Brisbane
Level 1, 200 Mary Street Brisbane QLD 4000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 7 3229 9860
RegistryWebsite RegistryEmail
Expand this box to read and print
name changed to TrivarX Ltd | 16/10/2023 |
The suspension of trading in the securities of Medibio Limited will be lifted immediately following the release by MEB of an announcement regarding a capital raising. | 22/06/2022 |
Commitments received for $1.4 million placement at $0.0015 (0.15 cents) per fully paid ordinary share. Issue price of $0.0015 (0.15 cents). Placement to be completed over two tranches. Investors under the placement to be offered one (1) free attaching option for every one (1) new share subscribed for, exercisable at $0.004 (0.4 cents) on or before an expiry date of 15 June 2027. Issue of securities under Tranche 2 are subject to shareholder approval, to be sought at an EGM to be held in August 2022. | 22/06/2022 |
The Company now expects to make an announcement in relation to the capital raising before the commencement of trading on 21 June 2022 and confirms its request that the suspension will continue until the announcement is made. | 20/06/2022 |
The securities of Medibio Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEB, pending the release of an announcement regarding a capital raising. | 16/06/2022 |
The suspension of trading in the securities of Medibio Limited will be lifted immediately following the release by MEB of an announcement regarding its capital raising. | 10/07/2019 |
Commitments were received for $3.5 million placement at $0.01 per fully paid ordinary share. SPP were on the same terms, underwritten for $520,000. Issue price of $0.01, a 51.6% discount to the 5-day VWAP. Placement to be completed over two stages. ✓ Investors under the placement and Eligible shareholders under the SPP to be offered 1 free attaching option for each new share subscribed for, exercisable at $0.03 until an expiry date of 1 December 2021 and for which the Company will seek quotation on the ASX. Existing holders of convertible notes have agreed to early conversion of their notes for fully paid ordinary shares at a conversion price equal to the issue price under the Placement. Each noteholder will be offered 1 free New Option for each Share issued. Issue of securities under Stage 2 of the Placement, the SPP (including underwritten shortfall) and the early conversion of notes is subject to shareholder approval, to be sought at an EGM to be held in late August 2019. | 10/07/2019 |
The securities of Medibio Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEB, pending the release of an announcement regarding a capital raising. | 09/07/2019 |
we understand that on or about this date the company consolidated its shares 1 for 100 | 20/03/2015 |
The suspension of trading in the securities of Medibio Limited (the "Company") will be lifted immediately following receipt of an announcement in relation to an agreement with John Hopkins Hospital. Security Code: MEB | 01/12/2014 |
name changed from Bioprospect Limited - was previously called MEDIA ASIA PACIFIC LIMITED which delisted from ASX on 31 August 1998 following the company's failure to lodge annual listing fees in respect of the year ended 30/06/99. | 01/12/2014 |
name changed to TrivarX Ltd | 16/10/2023 |
The suspension of trading in the securities of Medibio Limited will be lifted immediately following the release by MEB of an announcement regarding a capital raising. | 22/06/2022 |
Commitments received for $1.4 million placement at $0.0015 (0.15 cents) per fully paid ordinary share. Issue price of $0.0015 (0.15 cents). Placement to be completed over two tranches. Investors under the placement to be offered one (1) free attaching option for every one (1) new share subscribed for, exercisable at $0.004 (0.4 cents) on or before an expiry date of 15 June 2027. Issue of securities under Tranche 2 are subject to shareholder approval, to be sought at an EGM to be held in August 2022. | 22/06/2022 |
The Company now expects to make an announcement in relation to the capital raising before the commencement of trading on 21 June 2022 and confirms its request that the suspension will continue until the announcement is made. | 20/06/2022 |
The securities of Medibio Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEB, pending the release of an announcement regarding a capital raising. | 16/06/2022 |
The suspension of trading in the securities of Medibio Limited will be lifted immediately following the release by MEB of an announcement regarding its capital raising. | 10/07/2019 |
Commitments were received for $3.5 million placement at $0.01 per fully paid ordinary share. SPP were on the same terms, underwritten for $520,000. Issue price of $0.01, a 51.6% discount to the 5-day VWAP. Placement to be completed over two stages. ✓ Investors under the placement and Eligible shareholders under the SPP to be offered 1 free attaching option for each new share subscribed for, exercisable at $0.03 until an expiry date of 1 December 2021 and for which the Company will seek quotation on the ASX. Existing holders of convertible notes have agreed to early conversion of their notes for fully paid ordinary shares at a conversion price equal to the issue price under the Placement. Each noteholder will be offered 1 free New Option for each Share issued. Issue of securities under Stage 2 of the Placement, the SPP (including underwritten shortfall) and the early conversion of notes is subject to shareholder approval, to be sought at an EGM to be held in late August 2019. | 10/07/2019 |
The securities of Medibio Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEB, pending the release of an announcement regarding a capital raising. | 09/07/2019 |
we understand that on or about this date the company consolidated its shares 1 for 100 | 20/03/2015 |
The suspension of trading in the securities of Medibio Limited (the "Company") will be lifted immediately following receipt of an announcement in relation to an agreement with John Hopkins Hospital. Security Code: MEB | 01/12/2014 |
name changed from Bioprospect Limited - was previously called MEDIA ASIA PACIFIC LIMITED which delisted from ASX on 31 August 1998 following the company's failure to lodge annual listing fees in respect of the year ended 30/06/99. | 01/12/2014 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 09/11/2018 | Chris Indermaur | 200,000 | $0.040 | $8,000 |
| 06/11/2018 | Andrew Maxwell | 216,002 | $0.044 | $9,434 |
| 02/08/2017 | Andrew Maxwell | 26,000 | $0.380 | $9,880 |
| 10/07/2017 | Peter Carlisle | 5,500 | $0.373 | $2,053 |
| 18/04/2017 | Jack Cosentino | 100,000 | $0.370 | $37,000 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| David Trimboli | Non Exec Chairman | 25/08/2022 |
| Steve Sathre | CFO | 01/01/2019 |
| Lisa Heine | Non Exec Director | 29/08/2019 |
| Thomas R. Young | Non Exec Director | 19/09/2022 |
| Lisa Ide | Non Exec Director | 29/08/2019 |
| Chris Ntoumenopoulos | Non Exec Director | 15/02/2023 |
| Liwanag Ojala | Non Exec Director | 29/08/2019 |
| Stephen Buckley | Company Secretary |
Date of first appointment, title may have changed.
SPECIAL NOTE: During May 2024 we are working to remove duplications in the Company Secretary role.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Melanie Leydin | Non Exec Director | 22/02/2019 | 12/04/2023 |
| Matt Mesnik | Non Exec Director | 02/03/2022 | 16/03/2023 |
| Stephen Mitchley | Non Exec Director | 17/02/2022 | 11/11/2022 |
| Claude Solitario | Managing Director, CEO | 29/04/2014 | 22/06/2022 |
| Peter Carlisle | Independent Director | 05/06/2017 | 10/06/2022 |
| David Kaysen | Chairman, CEO | 02/11/2018 | 08/01/2020 |
| Patrick Kennedy | Non Exec Director | 04/07/2017 | 29/08/2019 |
| Franklyn Prendergast | Non Exec Director | 27/01/2016 | 29/08/2019 |
| Michael Phelps | Non Exec Director | 05/06/2017 | 29/08/2019 |
| Andrew Maxwell | Non Exec Director | 01/02/2017 | 22/02/2019 |
| Brian Mower | CFO | 24/04/2017 | 01/01/2019 |
| Chris Indermaur | Non Exec Chairman | 02/04/2015 | 31/12/2018 |
| Jack Cosentino | Managing Director, CEO | 16/02/2017 | 28/08/2018 |
| Adam Darkins | Deputy Chairman, Non Exec Director | 19/07/2017 | 19/01/2018 |
| Kris Knauer | Executive Director, CFO | 02/07/2014 | 13/10/2017 |
| Robert Lees | CFO | 28/09/2012 | 24/04/2017 |
| James Campbell | Non Exec Director | 07/09/2014 | 30/09/2016 |
| Vince Fayad | Non Exec Chairman | 29/04/2014 | 07/04/2015 |
| Silvi Elkhouri | Non Exec Director | 15/11/2013 | 08/09/2014 |
| Claude Solitario | Executive Director | 29/04/2014 | 08/09/2014 |
| Peter May | Non Exec Director | 01/11/2008 | 30/06/2014 |
| Benjamin Cooper | Executive Director | 10/04/2012 | 29/04/2014 |
| Winton Willesee | Chairman, Non Exec Director | 16/09/2011 | 15/11/2013 |
| Peter Pellegrino | Managing Director | 01/11/2009 | 19/11/2012 |
| Colin Johnston | CFO | 01/03/2004 | 28/09/2012 |
| Jacob Khouri | Non Exec Director | 16/02/2011 | 18/09/2012 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
